Skip to content

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Joan H. Schiller, David P. Harrington, Chandra Prakash Belani, Corey Jay Langer, Alan B. Sandler, James Edward Krook, Junming Zhu, David H. Johnson

New England Journal of Medicine · 2002 · 5,254 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Schiller, J. H., Harrington, D. P., Belani, C. P., Langer, C. J., Sandler, A. B., Krook, J. E., Zhu, J., & Johnson, D. H. (2002). Comparison of four chemotherapy regimens for advanced Non–Small-Cell lung cancer. New England Journal of Medicine, 346(2), 92–98. https://doi.org/10.1056/nejmoa011954

In text: (Schiller et al., 2002)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer. METHODS: A total of 1207 patients with advanced non-small-cell lung cancer were randomly assigned to a reference regimen of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel. RESULTS: The response rate for all 1155 eligible patients was 19 percent, with a median survival of 7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). Patients with a performance status of 2 had a significantly lower rate of survival than did those with a performance status of 0 or 1. CONCLUSIONS: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.

  1. Cancer statistics, 20222022
  2. Cancer Statistics, 20212021
  3. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening2011
  4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016
  5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015

Metadata from OpenAlex (CC0). Citations are generated from the published record.